Literature DB >> 7726876

Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty.

A Avendaño1, J J Ferguson.   

Abstract

OBJECTIVES: The aim of this study was to determine whether activated coagulation time measurements from Hemochron and HemoTec machines can be used interchangeably and whether similar activated coagulation time target ranges for adequate anticoagulation can be applied to both machines.
BACKGROUND: Adequate anticoagulation is necessary for the safe performance of intravascular interventions such as percutaneous transluminal coronary angioplasty. In current practice, anticoagulation status is frequently assessed by way of the activated coagulation time with one of two commercially available systems, HemoTec and Hemochron. Each one employs a different technique to determine the time of clot formation; however, the same target activated coagulation time values for adequate anticoagulation have been used interchangeably in published studies.
METHODS: A total of 311 paired samples were compared in 113 high risk patients undergoing angioplasty enrolled in a randomized trial of a platelet glycoprotein IIb/IIIa receptor antibody. Simultaneous activated coagulation time measurements were obtained before and after administration of heparin, and the difference between the values of both machines was calculated. The relation between the Hemochron and HemoTec values was determined by using linear regression analysis. All activated coagulation time measurements were classified as either therapeutic or subtherapeutic using an arbitrary activated coagulation time target of 300 s.
RESULTS: There was a correlation between values from the two machines (r = 0.86), but the Hemochron values were consistently higher than the HemoTec values by a mean value +/- SD of 28 +/- 29%, with wide individual variation. After heparin administration, there was a significant (p < 0.0001) difference between the number of measurements classified as therapeutic by HemoTec (53%) and by Hemochron (94%).
CONCLUSIONS: HemoTec and Hemochron activated coagulation time measurements cannot be used interchangeably. Appropriate target activated coagulation time ranges to determine adequate anticoagulation during coronary angioplasty need to be established for both machines; the target range for one machine should not be extrapolated to the other.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7726876     DOI: 10.1016/0735-1097(94)90636-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Monitoring Anticoagulation During Percutaneous Coronary Interventions.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.

Authors:  A P Schroeder; L L Knudsen; S E Husted; L Knudsen; J Ingerslev
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

3.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 5.  Heparin dose during percutaneous coronary intervention: how low dare we go?

Authors:  G Niccoli; A P Banning
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 6.  Unfractionated versus fractionated heparin for percutaneous coronary intervention.

Authors:  Heidar Arjomand; Satish K Surabhi; Marc Cohen
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

7.  Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.

Authors:  Ian J Welsby; Elizabeth McDonnell; Habib El-Moalem; Mark Stafford-Smith; John G Toffaletti
Journal:  J Clin Monit Comput       Date:  2002-07       Impact factor: 2.502

8.  Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.

Authors:  Harold L Dauerman; Steven A Ball; Robert J Goldberg; Melinda A Desourdy; Mark I Furman
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

9.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31

10.  Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.

Authors:  Jung Min Lee; Eun Young Park; Kyung Mi Kim; Jong Chan Won; Tack Koon Jung; Soo Kyung Lee
Journal:  J Int Med Res       Date:  2017-10-04       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.